Cargando…
SARS-CoV-2–neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma
Autores principales: | Malin, Jakob J., Di Cristanziano, Veronica, Horn, Carola, Pracht, Elisabeth, Garcia Borrega, Jorge, Heger, Eva, Knops, Elena, Kaiser, Rolf, Böll, Boris, Lehmann, Clara, Jung, Norma, Borchmann, Peter, Fätkenheuer, Gerd, Klein, Florian, Hallek, Michael, Rybniker, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683250/ https://www.ncbi.nlm.nih.gov/pubmed/34911078 http://dx.doi.org/10.1182/bloodadvances.2021006655 |
Ejemplares similares
-
Rezidivierende SARS-CoV-2-Infektionen bei Immundefizienz
por: Tometten, L., et al.
Publicado: (2022) -
Remdesivir against COVID-19 and Other Viral Diseases
por: Malin, Jakob J., et al.
Publicado: (2020) -
RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients
por: Eberhardt, Kirsten Alexandra, et al.
Publicado: (2020) -
A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2
por: Simonis, Alexander, et al.
Publicado: (2020) -
Importance of precise data on SARS-CoV-2 transmission dynamics control
por: Rybniker, Jan, et al.
Publicado: (2020)